# 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin

Study · id `cardio:ct-nct02647320` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02647320](<https://clinicaltrials.gov/study/NCT02647320>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02647320

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 298 participants.

## Technical summary

Registry record NCT02647320. Randomized; quadruple masking; primary purpose treatment. Start 2016-01 (registry gives no type); primary completion 2017-01-31 (actual). Results posted on 2018-05-01.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 298 participants (enrolled count; ClinicalTrials.gov record NCT02647320, source copy `cardio:ctgov-nct02647320-2019-02-25`, retrieved 2026-10-26)
- Start date: 2016-01 (registry gives no type) (ClinicalTrials.gov record NCT02647320, source copy `cardio:ctgov-nct02647320-2019-02-25`, retrieved 2026-10-26)
- Primary completion: 2017-01-31 (actual) (ClinicalTrials.gov record NCT02647320, source copy `cardio:ctgov-nct02647320-2019-02-25`, retrieved 2026-10-26)
- Completion: 2017-01-31 (actual) (ClinicalTrials.gov record NCT02647320, source copy `cardio:ctgov-nct02647320-2019-02-25`, retrieved 2026-10-26)
- Results first posted: 2018-05-01 (ClinicalTrials.gov record NCT02647320, source copy `cardio:ctgov-nct02647320-2019-02-25`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT02647320, source copy `cardio:ctgov-nct02647320-2019-02-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02647320-2019-02-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Sitagliptin 100 mg
- Intervention (Drug): DS-8500a 25mg
- Intervention (Drug): Placebo Tablet
- Intervention (Drug): Placebo Capsule
- Lead sponsor: Daiichi Sankyo
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)

## Provenance

Content hash: bd2ea30bb96780ab00f6b0b46ebe8135ee49c93ef7f7269dd2701526025c8e59
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
